Abstract #3538
Whole-Body MRI vs. Co-registered Whole-Body FDG-PET with MRI (PET/MRI) vs. Integrated FDG-PET/CT: Capability of Clinical Stage and Operability Assessments in Non-Small Cell Carcinoma
Yoshiharu Ohno 1 , Shinichiro Seki 2 , Mizuho Nishio 1 , Hisanobu Koyama 2 , Takeshi Yoshikawa 1 , Sumiaki Matsumoto 1 , Nobukazu Aoyama 3 , Kota Aoyagi 4 , Hitoshi Yamagata 5 , Hideaki Kawamitsu 3 , and Kazuro Sugimura 2
1
Advanced Biomedical Imaging Research Center,
Kobe University Graduate School of Medicine, Kobe,
Hyogo, Japan,
2
Radiology,
Kobe University Graduate School of Medicine, Kobe,
Hyogo, Japan,
3
Center
for Radiology and Radiation Oncology, Kobe University
Hospital, Kobe, Hyogo, Japan,
4
MClinical
Application Research Center, Toshiba Medical Systems
Corporation, Otawara, Tochigi, Japan,
5
Toshiba
Medical Systems Corporation, Otawara, Tochigi, Japan
Clinical stage assessment is important for treatment in
NSCLC patients. We hypothesized that whole-body MRI at
3T MR system, which is utilized multiple array coil with
parallel imaging capability and Quick 3D sequence with
DFS technique, has equal to or better potential for T, N
and M factors and operability assessments in NSCLC
patients than co-registered FDG-PET/MRI and integrated
FDG-PET/CT. The purpose of this study was to directly
compare the capability for clinical stage and
operability assessments among whole-body MRI,
co-registered FDG-PET/MRI and integrated FDG-PET/CT in
NSCLC patients.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
